| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 01/03/2003 | WO2003000896A2 POLYNUCLEOTIDES AND POLYPEPTIDES OF THE IFNα-5 GENE |
| 01/03/2003 | WO2003000889A2 Identification of ses-1 and the uses of the same |
| 01/03/2003 | WO2003000869A1 Transgenic animals and cells expressing proteins necessary for susceptibility to hiv infection |
| 01/03/2003 | WO2003000864A2 Nucleic acid-associated proteins |
| 01/03/2003 | WO2003000859A2 G-protein coupled receptors |
| 01/03/2003 | WO2003000846A2 A novel g protein-coupled receptor, gave 3 |
| 01/03/2003 | WO2003000844A2 Protein modification and maintenance molecules |
| 01/03/2003 | WO2003000778A1 Negatively charged amphiphilic block copolymer as drug carrier and complex thereof with positively charged drug |
| 01/03/2003 | WO2003000736A1 Humanized antibodies derived from dd-3b6/22, specific for the d-dimer fragment of fibrin |
| 01/03/2003 | WO2003000727A2 Atopy |
| 01/03/2003 | WO2003000721A2 Mycobacterial antigens expressed under low oxygen tension |
| 01/03/2003 | WO2003000717A2 Identification of ses-3 (spr-5) in c. elegans and the uses of the same |
| 01/03/2003 | WO2003000696A1 COMBINATION THERAPY OF AN SODm AND A CORTICOSTEROID FOR PREVENTION AND/OR TREATMENT OF INFLAMMATORY DISEASE |
| 01/03/2003 | WO2003000687A1 Tyrosine kinase inhibitors |
| 01/03/2003 | WO2003000682A1 (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds |
| 01/03/2003 | WO2003000666A1 5-ht receptor ligands and uses thereof |
| 01/03/2003 | WO2003000663A1 5-ht receptor ligands and uses thereof |
| 01/03/2003 | WO2003000343A2 Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation |
| 01/03/2003 | WO2003000308A1 Drug delivery devices |
| 01/03/2003 | WO2003000301A1 Combination of a ppar-alpha ligand and glucocorticoid for the treatment or prevention of inflammation |
| 01/03/2003 | WO2003000295A2 Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors |
| 01/03/2003 | WO2003000290A1 Antitumor agents |
| 01/03/2003 | WO2003000289A1 Composition comprising a pde-4 inhibitor and h1-receptor antagonist and the use thereof for the manufacture of a medicament for the treatment of respiratory diseases |
| 01/03/2003 | WO2003000285A1 Tissue-specific transporter inhibitor |
| 01/03/2003 | WO2003000273A1 Modulating serum amyloid a interaction with tanis and agents useful for same |
| 01/03/2003 | WO2003000268A1 Use of na+ channel blockers and aspirin in manufacturing drugs for producing analgesia synergistically in mammals |
| 01/03/2003 | WO2003000266A1 Novel quinolines and uses thereof |
| 01/03/2003 | WO2003000261A1 Use of bicyclo compounds for treating alzheimer's disease |
| 01/03/2003 | WO2003000256A1 Substituted oxazolidinones for combinational therapy |
| 01/03/2003 | WO2003000246A1 The use of rhein and derivatives thereof in pain treatment |
| 01/03/2003 | WO2003000243A1 Antimicrobial nanoemulsion compositions and methods |
| 01/03/2003 | WO2003000241A2 Novel pharmaceutical compositions based on anticholinergic agents, corticosteroids and betamimetic agents, for the treatment of inflammatory and/or obstructive respiratory tract diseases |
| 01/03/2003 | WO2003000239A1 Stable pharmaceutical compositions containing pravastatin |
| 01/03/2003 | WO2003000238A1 Pharmaceutical compositions of adsorbates of amorphous drug |
| 01/03/2003 | WO2003000209A1 Cosmetic or dermatological composition comprising n-acylaminoamide derivatives |
| 01/03/2003 | WO2003000200A2 β-2'-OR 3'-HALONUCLEOSIDES |
| 01/03/2003 | WO2003000196A2 Pharmaceutical compositions which inhibit proliferation of pituitary adenomas and method of use thereof |
| 01/03/2003 | WO2003000195A2 Method and material for treating immune diseases |
| 01/03/2003 | WO2003000191A2 Composition comprising glycosaminogycans and hyaluronidase inhibitors for the treatment of arthritic joints |
| 01/03/2003 | WO2003000185A2 Complex mixtures exhibiting selective inhibition of cyclooxygenase-2 |
| 01/03/2003 | WO2003000183A2 Method of treating atherosclerosis and other inflammatory diseases |
| 01/03/2003 | WO2003000181A2 Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| 01/03/2003 | WO2003000180A2 Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| 01/03/2003 | WO2003000177A2 Stable controlled release pharmaceutical compositions containing pravastatin |
| 01/03/2003 | WO2003000118A2 Method for enhancing the effectiveness of cancer therapies |
| 01/03/2003 | WO2003000117A2 Detection and treatment of prostate cancer |
| 01/03/2003 | WO2003000056A1 Joint lubrication with p2y purinergic receptor agonists |
| 01/03/2003 | WO2003000024A2 Uses of dc-sign and dc-signr for inhibiting hepatitis c virus infection |
| 01/03/2003 | WO2003000023A2 Method of treating hyperproliferative diseases using active vitamin d analogues |
| 01/03/2003 | WO2003000018A2 Dopamine agonist formulations for enhanced central nervous system delivery |
| 01/03/2003 | WO2002087596A3 Use of azithromycin for the manufacture of a medicament for treatment of non-infective inflammatory diseases |
| 01/03/2003 | WO2002076484A3 Combination of a taxane and a cyclin-dependent kinase inhibitor |
| 01/03/2003 | WO2002069960A3 Use of mek inhibitors for treating inflammation and virus induced hemorrhagic shock |
| 01/03/2003 | WO2002066020A3 Modulation of gsk-3beta activity and its different uses |
| 01/03/2003 | WO2002060869A3 Use of p38 inhibitors for the treatment of inflammation-enhanced cough |
| 01/03/2003 | WO2002046170A8 Anilinopyrimidine derivatives as jnk pathway inhibitors and compositions and methods related thereto |
| 01/03/2003 | WO2002044366A3 Retina-specific human proteins c70rf9, c120rf7, mpp4 and f379 |
| 01/03/2003 | WO2002040058A3 Hydroxyapatite-targeting poly(ethylene glycol) and related polymers |
| 01/03/2003 | WO2002026757A3 Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
| 01/03/2003 | WO2002026209A3 Microparticles for delivery of the heterologous nucleic acids |
| 01/03/2003 | WO2002024748A3 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 01/03/2003 | WO2002020764A3 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 01/03/2003 | WO2002012501A3 Anti-dual integrin antibodies, compositions, methods and uses |
| 01/03/2003 | WO2002012500A3 Anti-il-12 antibodies, compositions, methods and uses |
| 01/03/2003 | WO2002010387A3 G-protein coupled receptors |
| 01/03/2003 | WO2002009761A3 Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure |
| 01/03/2003 | WO2002009715A3 Use of an arylaldehyde 5-oxo-1, 2, 4-triazine hydrazide for the treatment of cancer |
| 01/03/2003 | WO2002009699A3 Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract |
| 01/03/2003 | WO2002008187A9 Novel peptides as ns3-serine protease inhibitors of hepatitis c virus |
| 01/03/2003 | WO2002005842A3 Preventing airway mucus production by administration of egf-r antagonists |
| 01/03/2003 | WO2002005791A3 Antitumor combination comprising an aromatase inhibitor and an egfr antagonist or inhibitor |
| 01/03/2003 | WO2002004611A3 Aminoacyl trna synthetases |
| 01/03/2003 | WO2002003976A3 Combinations of bisphosphonates, estrogenic agents and optionally estrogens |
| 01/03/2003 | WO2002002757A3 Adenylyl and guanylyl cyclases |
| 01/03/2003 | WO2002002603A3 Protein modification and maintenance molecules |
| 01/03/2003 | WO2002002131A3 Compositions and methods for the diagnosis and treatment of herpes simplex virus infection |
| 01/03/2003 | WO2002000724A3 Thymic stromal lymphopoietin receptor molecules and uses thereof |
| 01/03/2003 | WO2001098468A3 Proteases |
| 01/03/2003 | WO2001092528A3 Method of diagnosing, monitoring, staging, imaging and treating colon cancer |
| 01/03/2003 | WO2001089502A3 Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enzymes |
| 01/03/2003 | CA2633595A1 Antibodies against tumor-associated antigenic target (tat) polypeptides |
| 01/03/2003 | CA2489623A1 Atopy |
| 01/03/2003 | CA2455292A1 5-ht receptor ligands and uses thereof |
| 01/03/2003 | CA2455288A1 Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors |
| 01/03/2003 | CA2452049A1 Uses of dc-sign and dc-signr for inhibiting hepatitis c virus infection |
| 01/03/2003 | CA2451885A1 Method and material for treating immune diseases |
| 01/03/2003 | CA2451841A1 Method for enhancing the effectiveness of cancer therapies |
| 01/03/2003 | CA2451745A1 .beta.-2'-or 3'-halonucleosides |
| 01/03/2003 | CA2451686A1 A novel g protein-coupled receptor, gave 3 |
| 01/03/2003 | CA2451664A1 Use of bicyclo compounds for treating alzheimer's disease |
| 01/03/2003 | CA2451602A1 Combination therapy of an sodm and a corticosteroid for prevention and/or treatment of inflammatory disease |
| 01/03/2003 | CA2451250A1 Modulating serum amyloid a interaction with tanis and agents useful for same |
| 01/03/2003 | CA2451248A1 Composition comprising glycosaminoglycans and hyaluronidase inhibitors for the treatment of arthritic joints |
| 01/03/2003 | CA2451152A1 Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation |
| 01/03/2003 | CA2451026A1 Mycobacterial antigens expressed under low oxygen tension |
| 01/03/2003 | CA2450969A1 Nucleic acid-associated proteins |
| 01/03/2003 | CA2450954A1 Method of treating atherosclerosis and other inflammatory diseases |
| 01/03/2003 | CA2450942A1 Method of treating hyperproliferative diseases using active vitamin d analogues |
| 01/03/2003 | CA2450925A1 G-protein coupled receptors |
| 01/03/2003 | CA2450921A1 Protein modification and maintenance molecules |